Alan R. Elliott's profile photo

Alan R. Elliott

Washington, D.C.

Writer and Editor at Investor's Business Daily

Alan R. Elliott is a markets writer/editor with Investor’s Business Daily.

Articles

  • 1 week ago | investors.com | Alan R. Elliott

    Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning.

  • 2 weeks ago | investors.com | Alan R. Elliott

    The stock market's first-quarter reporting season rises to a roar in the coming week as Apple (AAPL), Amazon.com (AMZN), Exxon Mobil (XOM), Chevron (CVX), Caterpillar (CAT), Pfizer (PFE) and Eli Lilly (LLY) crowd onto the earnings calendar. Lilly and Amazon are the only ones expected to see notable earnings gains. And even those are projected to be significant slowdowns relative to their recent performance.

  • 3 weeks ago | investors.com | Alan R. Elliott

    The U.S. made clear over the past week it has focused its trade war primarily on China. In addition, the White House opened talks with Japan and at least Italy, if not the European Union, as trading partners attempt to barter down at least some of the barriers thrown up between the U.S. and the world. Stock market investors felt enough equilibrium to maintain the market's rally attempt begun on April 7. That puts IBD investors on the lookout for a follow-through day.

  • 3 weeks ago | investors.com | Alan R. Elliott

    Eli Lilly stock jetted higher early Thursday after a late-stage trial met the company's goals, advancing the contest to produce the industry's first oral weight-loss pill. Eli Lilly (LLY) said its orforglipron lowered blood sugar and body weight in patients with Type 2 diabetes, vs. a program of diet and exercise, in the first of several late-stage trials. The trials are part of a tight competition to move the booming weight-loss drug business to oral pills, vs.

  • 1 month ago | investors.com | Alan R. Elliott

    The market wraps up a week for the history books as the U.S. narrows an initially broad net of tariffs, in what appears to be an attempt to largely shut down trade between China and the U.S. As a result, the top ports in the U.S. are expected to be very quiet in the coming months. The Global Port Tracker report from the National Retail Federation and Hackett Associates projects a 23% decrease in container freight traffic to U.S. ports in June, compared to January.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
2K
Tweets
456
DMs Open
No
No Tweets found.